COMMUNIQUÉS West-GlobeNewswire

Clementia annonce le prix de son émission publique d’actions ordinaires

30/10/2018 - 02:21

MONTRÉAL, 29 oct. 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ : CMTA), une société biopharmaceutique au stade clinique proposant des traitements novateurs pour les personnes atteintes de troubles [...]

Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Precision Therapeutics Inc.: SEC File Nos. 001-36790; and 333-221966

30/10/2018 - 01:05

Precision Therapeutics Files Form S-4 Regarding Proposed Merger with Helomics Holding Corporation MINNEAPOLIS, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company [...]

REVA to Hold Third Quarter 2018 Financial Results Call

30/10/2018 - 00:20

SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) has scheduled a conference call to review its third quarter 2018 financial results and provide a business update. The [...]

CTD Holdings Announces Filing of Patent Application for Use of Hydroxypropyl Beta Cyclodextrins in the Treatment of Alzheimer’s Disease

29/10/2018 - 23:49

ALACHUA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, [...]

Hemispherx’s Presentation at the Dawson James Securities 4th Annual Small Cap Growth Conference to Be Livestreamed

29/10/2018 - 23:39

OCALA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, will [...]

Amedisys Reports Third Quarter 2018 Financial Results and Updates 2018 Guidance

29/10/2018 - 22:00

BATON ROUGE, La., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month period ended September 30, 2018. Three Month Periods Ended September 30 [...]

Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA® (voretigene neparvovec-rzyl) at American Academy of Ophthalmology Annual Meeting

29/10/2018 - 21:53

Use of different measurement for best-corrected visual acuity of participants in the Phase 3 clinical trial of LUXTURNA achieved statistically significant improvement versus control group Mutation subtype analysis [...]

Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma

29/10/2018 - 21:52

Company Announcement Phase III MAIA study of daratumumab in combination with lenalidomide and dexamethasone in front line multiple myeloma met the primary endpoint (PFS) at a pre-planned interim analysis demonstrating [...]

MPX Expands Maryland Footprint With Opening of Health for Life White Marsh Dispensary

29/10/2018 - 21:45

TORONTO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“ MPX ” or the “ Company ”) (CSE: MPX; OTC: MPXEF) announced that the Company will open a new Health for Life dispensary in Nottingham, Maryland [...]

Micron Solutions, Inc. Announces Changes to Executive Management and the Board of Directors

29/10/2018 - 21:39

FITCHBURG, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Micron Solutions, Inc. (NYSE American: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, [...]

Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer

29/10/2018 - 21:30

CAMBRIDGE, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and [...]

VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results

29/10/2018 - 21:30

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) [...]

Alder BioPharmaceuticals® to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results

29/10/2018 - 21:05

BOTHELL, Wash., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]

Assertio Therapeutics Announces the Appointment of Daniel A. Peisert as Senior Vice President and Chief Financial Officer; Current CFO Phil B. Donenberg to Retire November 30, 2018

29/10/2018 - 21:05

LAKE FOREST, Ill., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that Phillip B. Donenberg, Senior Vice President and Chief Financial Officer, will retire effective [...]

Pain Therapeutics Reports Third Quarter 2018 Financial Results

29/10/2018 - 21:05

- Phase IIa Study Initiation On-track for Q4 2018 - AUSTIN, Texas, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today reported financial results for the third [...]

GenMark Diagnostics Reports Third Quarter 2018 Results

29/10/2018 - 21:05

CARLSBAD, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the [...]

Aclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018

29/10/2018 - 21:01

WAYNE, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to [...]

Nuvectra® Reports Third Quarter 2018 Financial Results

29/10/2018 - 21:01

Reports Record Algovita ® Sales of $12.5 million, Up 98% YoY PLANO, Texas, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial [...]

AxoGen, Inc. Reports 2018 Third Quarter Financial Results

29/10/2018 - 21:01

Q3 Revenue of $22.7 million, representing 41% growth over prior year; Management reiterates full year 2018 guidance and introduces 2019 guidance ALACHUA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: [...]